Doses studied, not prescribed
Ipamorelin dosage in the research literature — what was given, to whom, by which route
This page reports doses from published studies in the third person. It is not a protocol and not a recommendation.
Read this first
Quick, plain framing before any numbers: this page describes the ipamorelin dosage amounts that appeared in published studies — what researchers gave to rats, ferrets, pigs, or trial volunteers, and by what route. It is reporting, not instruction. Nothing here tells you to take anything, because ipamorelin is not an approved medicine and there is no established human dose [3]. The human studies used intravenous dosing in controlled settings [2][3]. The community protocols people discuss online — usually subcutaneous and often paired with CJC-1295 — have no peer-reviewed human dosing basis and are described here only as anecdote, never as a recommendation. Where a number appears, it comes straight from a cited paper. The one figure that is genuinely useful and well-characterized is the half-life: about 2 hours in people [2].
Doses used in human studies
Human ipamorelin dosing exists in exactly two places in the literature, both intravenous. The 1999 PK/PD study gave healthy male volunteers single 15-minute IV infusions across five levels — 4.21, 14.02, 42.13, 84.27, and 140.45 nmol/kg — and observed dose-proportional kinetics with a single GH pulse peaking around 40 minutes [2]. The 2014 Phase 2 ileus trial gave 0.03 mg/kg IV twice daily for up to seven days to bowel-resection patients [3]. That is the entire human dosing record. Both were short, controlled, intravenous, and neither establishes a maintenance dose for any purpose — the trial didn't even meet its endpoint [3].
Doses used in animal studies
Animal dosing spans a wide range by design. A rat bone-growth study used subcutaneous ipamorelin at 18, 90, and 450 µg/day, divided three times daily for 15 days [4]. The 2024 ferret cachexia study used 1–3 mg/kg intraperitoneally [5]. Across the rodent literature the routes studied include intravenous (human PK and rodent efficacy), subcutaneous (the dominant route in community use), intranasal (~20% bioavailability in rodents), and intraperitoneal [5][4]. Note that ipamorelin itself is not orally bioavailable — only engineered analogs like NN703 were built for oral dosing, and that came at the cost of some hormonal selectivity [7]. These animal numbers do not translate to a human dose.
How much cjc-1295 ipamorelin should i take
There is no evidence-based answer to how much cjc-1295 ipamorelin should i take, and this page won't invent one. The CJC-1295 + ipamorelin combination has never been dosed in a controlled human trial for any outcome [3]. The subcutaneous "stack" regimens circulated in forums are anecdotal protocols with no peer-reviewed human dosing basis — they are not validated, not standardized, and not recommended here. What the literature does support is mechanism: the two peptides hit complementary GH-release pathways, which is the rationale people cite for pairing them [1]. But rationale is not a dose. Any number you see online is community lore, not science [3].
How to reconstitute cjc-1295 ipamorelin 5mg
Searches for How to reconstitute cjc-1295 ipamorelin 5mg are asking about lab handling of lyophilized (freeze-dried) peptide, not a clinical preparation, so here is the general research-supply context only. Ipamorelin is supplied as a lyophilized powder (free base or acetate salt) and is reconstituted with bacteriostatic water for research handling [2]. As a peptide it degrades with heat and repeated freeze-thaw, so reconstituted solution is typically kept refrigerated. These are general handling observations from the research-supply literature, not preparation instructions for human use — ipamorelin is not an approved drug and there is no clinical reconstitution protocol [3]. This site does not provide step-by-step preparation guidance.
Half-life and timing
This is the part of dosing that is actually well-characterized. In healthy human volunteers, ipamorelin's terminal half-life is approximately 2 hours, with clearance of 0.078 L/h/kg and a steady-state volume of distribution of 0.22 L/kg [2]. The GH response is a single discrete pulse peaking about 40 minutes (0.67 h) after dosing [2]. In rats, plasma clearance is roughly five-fold lower than GHRP-6 [1]. For the full timeline — including how long traces may linger and the anti-doping detection angle — see the dedicated how long does ipamorelin stay in your system page.
Why no human dose appears here
It bears repeating plainly: this page reports research doses and stops there. Ipamorelin has no approved indication, no Phase 3 data, and one Phase 2 trial that missed its endpoint [3]. There is no validated human dose to recommend, and recommending one would mean inventing it. The most honest, useful number on this entire page is the half-life — about 2 hours in people [2] — because it's the one figure backed by a clean human study. Everything else is study context, presented so you can read the literature for yourself, not a protocol to follow.